Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells - Wikidata - wikimedia - TriplyDB

Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells

Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells

http://www.wikidata.org/entity/Q28303091

about

Mass Spectrometry-Based Proteomics for Investigating DNA Damage-Associated Protein Ubiquitylation Role of the tumor microenvironment in mature B-cell lymphoid malignancies Drugging the undruggables: exploring the ubiquitin system for drug development Immunostimulatory Gene Therapy Using Oncolytic Viruses as Vehicles The role and mechanism of CRL4 E3 ubiquitin ligase in cancer and its potential therapy implications Immune Modulation in Hematologic Malignancies Targeting chronic lymphocytic leukemia cells in the tumor microenviroment: A review of the in vitro and clinical trials to date Regulating the Regulators: Recent Revelations in the Control of E3 Ubiquitin Ligases CAR T-Cell Therapy: The Role of Physical Barriers and Immunosuppression in Lymphoma Quantifying ubiquitin signaling Epigenetic regulation of fetal globin gene expression in adult erythroid cells Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomide Structural basis of lenalidomide-induced CK1α degradation by the CRL4(CRBN) ubiquitin ligase Cullin-RING ubiquitin E3 ligase regulation by the COP9 signalosome A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase Quantitative proteomics and terminomics to elucidate the role of ubiquitination and proteolysis in adaptive immunity The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective Recent advances in understanding multiple myeloma Precision medicine: from pharmacogenomics to pharmacoproteomics Trial Watch: Proteasomal inhibitors for anticancer therapy Thalidomide-induced teratogenesis: history and mechanisms DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation Lenalidomide for the treatment of B-cell lymphoma.CRL4A(CRBN) E3 ubiquitin ligase restricts BK channel activity and prevents epileptogenesis.Identification of cancer-cytotoxic modulators of PDE3A by predictive chemogenomics.Exploiting large-scale drug-protein interaction information for computational drug repurposing.Selective degradation of splicing factor CAPERα by anticancer sulfonamides.Solving the genetic puzzle of systemic lupus erythematosus.Structural studies reveal thalidomide's mechanism of action and clinical effects: crystal clear or clearly complexed?Hemoglobin switching's surprise: the versatile transcription factor BCL11A is a master repressor of fetal hemoglobin.Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.p97/VCP promotes degradation of CRBN substrate glutamine synthetase and neosubstrates.A covalently bound inhibitor triggers EZH2 degradation through CHIP-mediated ubiquitination.Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma.The ubiquitin-conjugating enzyme UBE2O modulates c-Maf stability and induces myeloma cell apoptosis Internal ribosome entry site of bFGF is the target of thalidomide for IMiDs development in multiple myeloma.Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma.New mechanism of lenalidomide activity.Targeting Splicing in the Treatment of Myelodysplastic Syndromes and Other Myeloid Neoplasms.

P2860

Q26744515-217FAA5D-CF09-403A-A983-BA7358E5548F Q26748775-97534B76-496B-47D7-9F05-9F17A9376836 Q26752823-547D6D0A-E3F8-4ED7-BF53-8B024FC0E37A Q26777403-7AC3BF2A-BF38-46A5-A375-A949DDE81F72 Q26783814-306D5CB5-E517-4357-B190-6C10AF1BB113 Q26796307-7BC04E2E-B438-40DD-953A-0337D8CC0DCA Q26798062-D95A3519-1EB5-4A75-9008-F94DBC55B116 Q26799441-622EBBE7-1EEA-4413-A6DB-F761BE2746E0 Q26800814-08287FDC-0985-4681-BB7D-76D6B02E13CE Q26823466-AE964492-0422-4FA6-96EA-4505FC720581 Q26864609-993502C9-AA0B-4165-84F7-457043ECA51E Q27684738-C7FCC19A-EA1F-40A4-A7DB-5761E8D45F07 Q27704179-F3DA2379-6029-4BC5-9646-9CAA1C540E5B Q27704406-073ADB50-CC92-4163-AD3C-4E8FD5D7E97F Q27713259-ECEF39B6-F841-455C-8C92-168AA22FA18B Q28069531-38E63A5B-ED92-4246-BB6C-7560EC716C6E Q28069789-BCBCEE91-74EF-4D65-9430-9D6A277A711A Q28070331-1C097399-2126-456A-A1D9-282214E2CEBD Q28076871-B4EF431B-C17A-4A0F-BE05-60E54CE72451 Q28082910-E531AA4C-BF97-4054-8948-D90866D299D1 Q28085087-13C189B1-A900-4C54-80EC-56860BE42BD1 Q28830958-9655C750-88A5-4F30-A045-43197BCC8FC9 Q30249007-D0A80845-F703-4FE0-B75F-84E02FCD33A2 Q30362741-58212D7E-00A7-4562-9FFC-F1C51C7306AD Q30381467-F5B9A1DC-ACBA-4A67-9C6B-5BADB44EE7FD Q30582560-119B6D7D-1249-4DB6-9D46-20AE9AA8DB5C Q33112699-91C4819F-F42B-4A05-9BB8-02B940F170FA Q33359121-CCF218FF-93BF-4B5F-BD90-A2A1513D356F Q33360075-F1C99F99-4545-4DAB-AA19-C3D24494E1EC Q33361527-50AABE91-8EE4-4626-BDEC-67EF92D388E0 Q33417117-8FE4CE76-6466-4E4C-A6BD-CC39167C9B24 Q33418964-3AD9583B-D4E4-4505-AFBC-E4D66A7B8267 Q33556826-768D0DBB-344A-434A-BB98-94A7EBEAEE8E Q33626131-35DC3A8C-F7E3-4F88-B1C0-3D8F935C51C3 Q33846806-539EE1DF-38AF-4616-81B4-020ED5A95C0E Q33869569-20ABABB2-912E-41C7-AB2F-F534F6EB10EC Q33880085-29DB1D02-7EE9-47E0-B2AB-68962FF2CD6C Q33948719-F02F472B-0968-4197-B288-13C34878DB26 Q33989991-BB6B0F35-C23A-4652-8000-7B9C71D58FBB Q34047259-E5CD37EE-A07F-4F51-AC62-74475CF933D7

P2860

Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells

http://www.wikidata.org/entity/Q28303091

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

name

Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells

@ast

Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells

@en

Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells

@nl

type

label

Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells

@ast

Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells

@en

Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells

@nl

prefLabel

Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells

@ast

Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells

@en

Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells

@nl

P1433

Q28303091-22EF6040-3ADC-4A84-B9D8-59C0CE064740

P1476

Q28303091-25AF897C-83EB-4AD0-971E-7C1E65557D49

P2093

Q28303091-07CFC665-29C8-4871-84D1-54F7BA792123

Q28303091-350DEBF9-4EC6-4011-9C1E-49DE227E4178

Q28303091-4CB330A3-6194-4F9B-BE8E-E5607C5F4C93

Q28303091-6A0AC111-E7D1-4367-B0C4-67DF46F19976

Q28303091-8A43C300-EF62-49E9-BDA3-EEAB54AF2A26

Q28303091-9B3CDD01-5EC3-42E8-969F-3599F170EC87

Q28303091-9FFD3276-F72E-4BDD-8FDB-E312A3D27341

Q28303091-A20E4BF2-4CAD-457A-A640-053C54A0D981

Q28303091-A2E1446B-FAEE-496D-BF60-91359D448992

Q28303091-AAFDC500-E05D-4826-B0C4-7074E3C10E89

P2860

Q28303091-1302F087-3EAA-427A-9365-B0FE2EB3AD7F

Q28303091-179C19A0-A666-4868-BD25-4BF459D35C97

Q28303091-1918A283-7484-4AC7-BE19-1FF4AA6C1C89

Q28303091-1B4254F3-16FA-4088-A48A-26BE40AB3C79

Q28303091-246E4450-ADED-4605-921A-ECC90C495FAC

Q28303091-2C4B8162-0EC9-4AB0-8829-9B4FA66FE61D

Q28303091-35191CC2-5E4A-4DB2-A9BE-5B3BDC57A1EE

Q28303091-48458914-4D49-41A5-BEC1-45755789C310

Q28303091-5503492C-A0C9-4008-9AA9-7B173A601BF1

Q28303091-5C55927E-35D6-4141-B901-9FF8F85637AA

P304

Q28303091-DC604D0C-A928-473F-8403-E3C38528FEB8

P31

Q28303091-44F9E388-35BC-46F1-B1A7-11E15284F443

P3181

Q28303091-4A2E6DB9-1E5A-4B96-B5A9-C7E18242E516

P356

Q28303091-77C4DE03-5D9C-4661-9CEA-4BD8A8404A7C

P407

Q28303091-433228E1-D34F-4718-9044-E151E3E384B2

P433

Q28303091-47E85076-5A61-4556-AA8F-C14E53C9F1A3

P478

Q28303091-1A28D956-445D-4841-BEEE-A53123567D8C

P577

Q28303091-D6372133-2047-41EB-BE05-C57FB3F7A1A3

P5875

Q28303091-52EE5752-4C5E-4B5A-AD29-CF9C2218F32F

P698

Q28303091-E5B8169C-C042-4A2E-9006-B682A531F2E0

P932

Q28303091-393F289A-6D38-478C-9960-2A42F8DC4E4E

P3181

P356

SCIENCE.1244851

P1433

P1476

Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells

@en

P2093

Anupama Narla

http://www.w3.org/2001/XMLSchema#string

Benjamin L Ebert

http://www.w3.org/2001/XMLSchema#string

Christie Ciarlo

http://www.w3.org/2001/XMLSchema#string

Dirk Heckl

http://www.w3.org/2001/XMLSchema#string

Eamon Comer

http://www.w3.org/2001/XMLSchema#string

Emily Hartman

http://www.w3.org/2001/XMLSchema#string

Jan Krönke

http://www.w3.org/2001/XMLSchema#string

Marie McConkey

http://www.w3.org/2001/XMLSchema#string

Monica Schenone

http://www.w3.org/2001/XMLSchema#string

Namrata D Udeshi

http://www.w3.org/2001/XMLSchema#string

P2860

Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell-like and Foxp3(+) regulatory T cells

The ubiquitin ligase activity in the DDB2 and CSA complexes is differentially regulated by the COP9 signalosome in response to DNA damage

Identification of a primary target of thalidomide teratogenicity

Molecular architecture and assembly of the DDB1-CUL4A ubiquitin ligase machinery

Aiolos, a lymphoid restricted transcription factor that interacts with Ikaros to regulate lymphocyte differentiation

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide

Mechanism of auxin perception by the TIR1 ubiquitin ligase

RING domain E3 ubiquitin ligases

A practical recipe for stable isotope labeling by amino acids in cell culture (SILAC)

The Ikaros gene is required for the development of all lymphoid lineages

P304

301-5

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

812016

http://www.w3.org/2001/XMLSchema#string

P356

10.1126/SCIENCE.1244851

http://www.w3.org/2001/XMLSchema#string

P407

P433

6168

http://www.w3.org/2001/XMLSchema#string

P478

343

http://www.w3.org/2001/XMLSchema#string

P577

2014-01-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259110094

http://www.w3.org/2001/XMLSchema#string

P698

24292625

http://www.w3.org/2001/XMLSchema#string

P932

4077049

http://www.w3.org/2001/XMLSchema#string